The pro-proliferative signaling triggered by BCR–ABL1 can be blocked by tyrosine kinase inhibitors (TKIs), which has dramatically improved the prognosis of many CML patients [2]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.